KOOP MMA chairman and eMedAsia director Dr Thirunavukarasu.

       PETALING JAYA: Hong Seng Consolidated Bhd’s subsidiary eMedAsia Sdn Bhd has further expanded its agreement with CLEA Technology Sdn Bhd in relation to the exclusive collaboration for provision of virtual Covid-19 screening.

       In the detailed agreement, eMedAsia and CLEA expressed their intention to expand on the

       services and conveniences offered to the Health Ministry (MOH) and other authorities involved in the opening of the country’s borders.

       Following the government’s latest protocol with regards to the requirements and SOP for virtual

       RTK-Ag testing as an alternative Covid-19 screening method, both parties are desirous in

       collaborating with each other to provide Covid-19 professional RTK-Ag testing via CLEADOC Virtual Screening’s in-app methodology which are in compliance with MOH’s

       requirements and guidelines, supervised by a panel doctor from CLEADOC’s panel listing.

       Koperasi Persatuan Perubatan Malaysia (KOOP MMA) chairman and eMedAsia director Dr Thirunavukarasu Rajoo said, “In addition to our recent Collaboration Agreement with CLEA, both parties have agreed to further expand its range of offerings in order to facilitate a successful border reopening for Malaysia.

       “We have agreed to share all revenue on a 50:50 basis.”

       Currently, the rate for the service charges under the virtual RTK-Ag testing is set at RM25

       to users but may change from time to time.

       Under the latest agreement, CLEADOC will also be onboarding more clinics and doctors to

       participate in the services arising from the testing, provide support services as required by the

       relevant authorities, as well as ensure all infrastructure, support or any other features including

       the service levels shall conform to the authorities’ requirements including any changes from time

       to time.

       On April 6, 2022, eMedAsia entered into an exclusive partnership with CLEA, the first

       company that provides CLEADOC Virtual Covid-19 Professional RTK and PCR Screenings

       (VCS) and other related services in Malaysia.

       Through the partnership which involves exclusive backend system integrations, eMedAsia, a

       60%-owned subsidiary under the group’s healthcare arm HS Bio Group in partnership with

       KOOP MMA which is in turn the investment arm of the Malaysia Medical Association (MMA) will be able to provide CLEADOC VCS services to both the inbound and outbound travellers as preparation for the next phase of border reopening.